Get the Stockscreener App
82.91
0.50%
-0.42
After Hours:
82.83
-0.08
-0.10%
Edwards Lifesciences Corp stock is traded at $82.91, with a volume of 3.29M.
It is down -0.50% in the last 24 hours and up +2.29% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$83.33
Open:
$83.95
24h Volume:
3.29M
Relative Volume:
0.64
Market Cap:
$47.80B
Revenue:
$6.30B
Net Income/Loss:
$1.07B
P/E Ratio:
45.05
EPS:
1.8406
Net Cash Flow:
$1.34B
1W Performance:
+0.77%
1M Performance:
+2.29%
6M Performance:
+0.08%
1Y Performance:
+10.38%
1-Day Range:
$81.42
$83.95
1-Week Range:
$80.65
$85.06
52-Week Range:
$72.30
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
[Form 4] Edwards Lifesciences Corp Insider Trading Activity - Stock Titan
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
Edwards Lifesciences Appoints Theodora Mistras as Chief Financial Officer Effective May 2026 - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Edwards Lifesciences CVP, TAVR, sells $170,160 in stock - Investing.com
Edwards Lifesciences (EW) CVP Lippis sells 2,038 shares after option exercises - Stock Titan
Edwards Lifesciences (EW) executive logs 282-share tax withholding on Form 4 - Stock Titan
Edwards Lifesciences (EW) VP Donald Bobo logs tax share disposal and holdings - Stock Titan
Edwards Lifesciences names Doretta Mistras as new CFO - Investing.com
Theodora Mistras to Become Edwards Lifesciences CFO, Succeeding Scott Ullem - TradingView
New Edwards Lifesciences (NYSE: EW) CFO to receive $925K salary and major equity - Stock Titan
Edwards picks Viatris finance chief Doretta Mistras as CFO - Stock Titan
Edwards Lifesciences (NYSE: EW) files Form 144; insider disposals listed - Stock Titan
Possible Bearish Signals With Edwards Lifesciences Insiders Disposing Stock - Yahoo Finance
TEN-YEAR PIVOTAL DATA REINFORCE THE LONG-TERM DURABILITY OF EDWARDS' RESILIA TISSUE - Yahoo Finance
PFA Pension Forsikringsaktieselskab Buys Shares of 543,261 Edwards Lifesciences Corporation $EW - MarketBeat
M&T Bank Corp Cuts Position in Edwards Lifesciences Corporation $EW - MarketBeat
Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue - The Norfolk Daily News
Edwards Lifesciences Corporation $EW Stake Lessened by Kornitzer Capital Management Inc. KS - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Caisse Des Depots ET Consignations - MarketBeat
Exencial Wealth Advisors LLC Trims Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Barclays Lifts PT on Edwards Lifesciences Corporation (EW) Following Q1 Earnings - Insider Monkey
EW Technical Analysis | Trend, Signals & Chart Patterns | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Jennison Associates LLC Sells 178,259 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
How The Edwards Lifesciences (EW) Investment Story Is Shifting As Views On Growth Diverge - Yahoo Finance
Edwards Lifesciences Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
Vanguard (NYSE: EW) reports 43.48M shares, 7.54% stake in Edwards Lifesciences - Stock Titan
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Edwards CEO speaks May 12, with live webcast and same-day replay - Stock Titan
AMG National Trust Bank Takes Position in Edwards Lifesciences Corporation $EW - MarketBeat
Vanguard Group Inc. Sells 283,775 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
MDEV volume surges 14x as Edwards Lifesciences jumps - TipRanks
US28176EAD04 Bond Analysis — Key Metrics - TradingView
Munich Reinsurance Co Stock Corp in Munich Purchases 52,494 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
A Look at Edwards Lifesciences Corp (EW) After 5.6% Gain -- GF V - GuruFocus
Edwards Lifesciences Stock Surges On Heart Valve Devices Growth - Benzinga
Edwards raises 2026 guidance on strong TAVR performance - BioWorld News
Edwards Lifesciences jumps 5.2% as Q1 results top expectations and full-year guidance rises - Quiver Quantitative
Edwards Lifesciences raises FY26 guidance following strong Q1 - Yahoo Finance
TD Cowen reiterates Edwards Lifesciences stock Buy rating on strong Q1 results - Investing.com
Bernstein SocGen raises Edwards Lifesciences stock price target to $96 - Investing.com
Stifel reiterates Edwards Lifesciences stock rating on strong Q1 beat - Investing.com
Stifel reiterates Edwards Lifesciences stock rating on strong Q1 beat By Investing.com - Investing.com Canada
Edwards Lifesciences (NYSE:EW) Given New $87.00 Price Target at Robert W. Baird - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00 at BTIG Research - MarketBeat
OLD National Bancorp IN Sells 16,066 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Bernstein Adjusts PT on Edwards Lifesciences to $96 From $95, Maintains Market Perform Rating - marketscreener.com
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):